Welcome to our dedicated page for Dynavax Technolo SEC filings (Ticker: DVAX), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
Dynavax Technologies Corp. filings document its vaccine business, public-company governance and corporate-status transition. The record includes 8-K reports for financial results, Regulation FD clinical disclosures for Z-1018, management realignment, material agreements and merger-related events, alongside securities information for its common stock.
Later filings include a Form 25 filed by Nasdaq for removal of Dynavax common stock from listing and registration, and a Form 15 covering termination or suspension of Exchange Act reporting obligations. These documents frame the company's transition from Nasdaq-listed issuer reporting toward deregistration while preserving formal disclosures on capital structure, governance and material events.
Dynavax Technologies Corporation furnished an update on its business by announcing financial results for the third quarter ended September 30, 2025 and unveiling a new $100 million share repurchase program via an accompanying press release. The press release was furnished as Exhibit 99.1 and provides the detailed results and program terms.
This 8-K indicates the results and buyback authorization were communicated through a press release that is incorporated by reference for informational purposes, while the 8-K itself notes the information is furnished, not filed under the Exchange Act. Shares of DVAX continue to trade on the Nasdaq Global Select Market.
Dynavax Technologies Corporation announced leadership changes tied to an internal realignment. Effective January 1, 2026, David F. Novack will transition from President and Chief Operating Officer to Senior Vice President and Chief Operating Officer.
The Board approved the removal of Robert Janssen, M.D. from his roles as Chief Medical Officer and Senior Vice President, Clinical Development, Medical and Regulatory Affairs, effective upon the earlier of the Company hiring a new Chief Medical Officer or March 2, 2026. Dr. Janssen’s employment will conclude as of March 2, 2026. The Company has commenced a search for a successor Chief Medical Officer.
Deep Track Biotechnology Master Fund, Ltd., Deep Track Capital, LP and individual David Kroin report shared beneficial ownership of 15,726,349 shares of Dynavax Technologies Corporation common stock, representing 13.41% of the 117,267,482 shares outstanding cited in the filing. The filing is Amendment No. 2 to a prior Schedule 13G/13D series and states the Reporting Persons are eligible to report on Schedule 13G under Rule 13d-1(h), replacing the prior Schedule 13D disclosures.
The cover-page details show the Reporting Persons have no sole voting or dispositive power and only shared voting and dispositive power over the reported shares.
Deep Track Biotechnology Master Fund, Ltd., Deep Track Capital, LP and individual David Kroin report shared beneficial ownership of 15,726,349 shares of Dynavax Technologies Corporation common stock, representing 13.41% of the 117,267,482 shares outstanding cited in the filing. The filing is Amendment No. 2 to a prior Schedule 13G/13D series and states the Reporting Persons are eligible to report on Schedule 13G under Rule 13d-1(h), replacing the prior Schedule 13D disclosures.
The cover-page details show the Reporting Persons have no sole voting or dispositive power and only shared voting and dispositive power over the reported shares.
Dynavax Technologies director Scott Myers purchased 3,800 shares of Dynavax Technologies Corp (DVAX) on 08/22/2025 at $10.82 per share in an open-market transaction. After the purchase he beneficially owns 35,004 shares, reported as direct ownership. The Form 4 was filed by a single reporting person and signed on 08/25/2025 by an attorney-in-fact. The filing discloses only this non-derivative common stock purchase; no options, dispositions, or additional transactions are reported.
Dynavax Technologies (DVAX) insiders reported two open-market dispositions on Aug 21-22, 2025. Deep Track Biotechnology Master Fund, Ltd., Deep Track Capital, LP and David Kroin (reported as director/10% owners) sold 1,094,994 shares on 08/21/2025 at $11.03 and 970,143 shares on 08/22/2025 at $10.59. After those transactions the Reporting Persons reported beneficial ownership of 16,696,492 shares following the first sale and 15,726,349 shares following the second sale; ownership is reported as indirect. The Form 4 is filed jointly by the three Reporting Persons and includes signed disclosures clarifying possible pecuniary interests and shared voting/disposition power.
Dynavax Technologies Corporation reported that it has released topline results from Part 1 of its Phase 1/2 clinical trial of Z-1018, its novel shingles vaccine candidate. The study is randomized, observer-blinded, and active-controlled, testing Z-1018 head-to-head against Shingrix in adults aged 50 to 69 years. Dynavax also updated its corporate presentation to include information on this Phase 1/2 trial, and both the press release and presentation are provided as exhibits to the report.